Immunological gene therapy approaches for malignant melanoma. 2. Preclinical studies and clinical strategies.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Skin Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1159/000211476PMID 9287392
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant

  2005cited by this paper
• Immunological gene therapy approaches for malignant melanoma. 1. Tumor-immunological background.

  1997cited by this paper
• A new foreign policy: MHC class I molecules monitor the outside world.

  1996cited by this paper
• Adenoviral-mediated herpes simplex virus-thymidine kinase gene transfer in vivo for treatment of experimental human melanoma.

  1996cited by this paper
• Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene.

  1996cited by this paper
• Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?

  1996cited by this paper
• Successful Culture and Selection of Cytokine Gene-Modified Human Dermal Fibroblasts for the Biologic Therapy of Patients with Cancer

  1996cited by this paper
• Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene.

  1996cited by this paper
• Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.

  1996cited by this paper
• IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells

  1996cited by this paper
• Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.

  1996cited by this paper
• Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.

  1996cited by this paper
• Loss of Tumorigenicity and Increased Immunogenicity Induced by Interleukin-10 Gene Transfer in B16 Melanoma Cells

  1996cited by this paper
• Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene.

  1995cited by this paper
• Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor.

  1995cited by this paper
• Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.

  1995cited by this paper
• Paracrine cytokine adjuvants in cancer immunotherapy.

  1995cited by this paper
• Manipulation of costimulatory signals to enhance antitumor T-cell responses.

  1995cited by this paper
• Rejection of mouse melanoma elicited by local secretion of interleukin‐2: Implicating macrophages without T cells or natural killer cells in tumor rejection

  1995cited by this paper
• A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401.

  1995cited by this paper
• Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in vivo.

  1995cited by this paper
• In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine.

  1995cited by this paper
• Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model.

  1995cited by this paper
• Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters.

  1995cited by this paper
• Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation

  1995cited by this paper
• In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.

  1995cited by this paper
• Generation of Therapeutic T‐Lymphocytes After In Vivo Tumor Transfection with an Allogeneic Class I Major Histocompatibility Complex Gene

  1995cited by this paper
• Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma

  1995cited by this paper
• Exposing the immunology of naked DNA vaccines.

  1995cited by this paper
• End-of-the-Year Potpourri—1995

  1995cited by this paper
• A reassessment of the role of B7-1 expression in tumor rejection

  1995cited by this paper
• IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts.

  1995cited by this paper
• Pilot study for the evaluation of T-cell-mediated tumor immunotherapy by cytokine gene transfer in patients with malignant tumors

  1995cited by this paper
• Targeted gene therapy.

  1995cited by this paper
• Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study.

  1994cited by this paper
• Melanoma-derived interleukin 6 inhibits in vivo melanoma growth.

  1994cited by this paper
• Monoclonal Antibody Gene Transfer: Implications for Tumor‐Specific Cell‐Mediated Cytotoxicity a

  1994cited by this paper
• Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma.

  1994cited by this paper
• Safety and Toxicity of Catheter Gene Delivery to the Pulmonary Vasculature in a Patient with Metastatic Melanoma

  1994cited by this paper
• Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.

  1994cited by this paper
• Retrovirus-mediated gene transfer of the human gamma-IFN gene: a therapy for cancer.

  1994cited by this paper
• Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.

  1994cited by this paper
• Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulate predetermined classes of anti-melanoma effector cells.

  1994cited by this paper
• Mechanisms of Tumor Regression of TNF Gene‐Transduced Meth‐A Cells Transplanted in Mice

  1994cited by this paper
• MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens

  1994cited by this paper
• Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

  1994cited by this paper
• Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells

  1994cited by this paper
• Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

  1994cited by this paper
• The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity.

  1994cited by this paper
• Enhancement of Immune Reactivity in the Lymph Nodes Draining a Murine Melanoma Engineered to Elaborate Interleukin‐4

  1994cited by this paper
• A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes.

  1994cited by this paper
• The role of IL-2 in gene therapy.

  1994cited by this paper
• Increasing tumour immunogenicity by genetic modification.

  1994cited by this paper
• Immunotherapy for Cancer by Direct Gene Transfer into Tumors. Howard Hughes Medical Institute Research Laboratories, Ann Arbor, Michigan

  1994cited by this paper
• The immunobiological effects of interleukin-2 in vivo

  1994cited by this paper
• MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.

  1994cited by this paper
• Cancer escape from immune surveillance: how can it be overcome by gene transfer?

  1994cited by this paper
• Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response.

  1994cited by this paper
• A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma.

  1994cited by this paper
• Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma.

  1994cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• The effects of rhGM-CSF on macrophage function.

  1993cited by this paper
• Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans.

  1993cited by this paper
• Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design.

  1993cited by this paper
• Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism.

  1993cited by this paper
• Immunization with Interleukin-2 Transfected Melanoma Cells. A Phase I–II Study in Patients with Metastatic Melanoma. University Hospital Leiden

  1993cited by this paper
• Adenoviral Interleukin-2 Gene Transfer into P815 Tumor Cells Abrogates Tumorigenicity and Induces Antitumoral Immunity in Mice

  1993cited by this paper
• Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.

  1993cited by this paper
• Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells.

  1992cited by this paper
• Use of T-Cell Growth Factors (Interleukins 2, 4, 7, 10, and 12) in the Evaluation of T-Cell Reactivity to Melanoma

  1992cited by this paper
• Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.

  1992cited by this paper
• A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma.

  1992cited by this paper
• Interleukin 7 induces CD4+ T cell-dependent tumor rejection

  1991cited by this paper
• Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

  1990cited by this paper
• Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.

  1990cited by this paper
• Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens.

  1984cited by this paper

• Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells

  2009cites this paper
• Malignant melanoma--future prospects.

  2005cites this paper
• Dermatologic Diseases and Problems

  2003cites this paper
• Imiquimod, a Topical Immune Response Modifier, in the Treatment of Cutaneous Metastases of Malignant Melanoma

  2002cites this paper
• Melanoma Techniques and Protocols

  2001cites this paper
• Malignant melanoma.

  2001cites this paper
• Role of molecular biology in diagnostic pathology of melanoma.

  2001cites this paper
• Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs.

  2001cites this paper
• Malignant melanoma: An update

  2001cites this paper
• Advances in specific immunotherapy of malignant melanoma.

  2000cites this paper
• Tumor tissue recycling--a new combination treatment for solid tumors: experimental and preliminary clinical research.

  1999cites this paper
• Treatment of Malignant Melanoma

  1999cites this paper
• Targeting Melanoma with 211 At/131I-Methylene Blue: Preclinical and Clinical Experience

  1999cites this paper
• Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis.

  1998cites this paper
• Adenovirus-mediated ex vivo immunogene and in vivo combination gene therapy strategies induce a systemic anti-tumor immune defense in the mouse B16 melanoma model.

  1998cites this paper
• Gene therapy for melanoma in humans.

  1998cites this paper
• Prise en charge du mélanome cutané

  1998cites this paper
• [Managing cutaneous melanoma].

  1998cites this paper
• Early detection of melanoma metastases with radioiodinated methylene blue

  1998cites this paper